TYLT Lab

TYLT Lab was founded in 213 and has offices in Santa Monica CA and in Hong Kong. TYLT Lab invests across a variety of sectors including biotech and medical technology and will be raising a second fund in 215. TYLT Lab typically invests $5-$1 million and prefers to invest in seed or Series A rounds. The firm makes up to 12 allocations per year and is interested in opportunities globally, companies developing products that can impact healthcare delivery in emerging markets such as China or India are of particular interest.
Gerard Casale
Managing Director 

Ventac Partners United States

Ventac Partners is a dedicated life science investment and consulting firm with offices in Europe, USA and Asia. Ventac Partners has a strong track record in founding new innovative companies, fund raising and supporting M&A transactions.

All partners are experienced and hands-on life science entrepreneurs with proven track-record in successfully starting, funding, growing and expanding international life science companies.

Neil Thomas
Neil Thomas
LinkedIn logo Partner 

Walter Greenblatt & Associates United States

Our clients are early-stage biotechnology, medical device, diagnostics and pharmaceutical service companies. When we begin working with a client they are frequently looking to complete proof-of-concept studies, secure intellectual property and other critical preliminary tasks. Typically we raise the first round ($1 - $5 million of capital) needed to accomplish these milestones, usually, but not always from angel investors. After key milestones have been achieved using that money, we generally follow by raising a second round of $5-20 million, usually institutional money, for development and growth

By working this way, we increase our clients' success rate raising capital and building their companies and the returns to the investors we bring into those companies. We have raised over $80 million in early stage funding for our clients (in Seed, Series A and Series B rounds) and delivered realized returns, so far, over $500 million—a realized return to date of over 6X—to the investors who provided that early stage capital, with a number of the companies still driving towards an exit that may increase that figure. Realized (cash-on-cash) internal rates of return for a hypothetical investor who participated in each round of financing offered by WG&A to date exceeds 65% annually.

Walter Greenblatt
Managing Director 

Wellington Partners Germany

Wellington Partners is a venture capital firm based in Munich, Germany, with an additional office in Zurich, Switzerland. The firm specializes in early-stage and growth capital investments in the Technology and Life Sciences sector. The firm has approximately €800M AUM and is currently investing out of a €100M fund for Life Science companies. Depending on the stage of the company, the firm can allocate up to €10M over the life of the investment. The firm can also lead or co-lead financing rounds of up to €30M or higher with syndicates. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

Year Founded
1990
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Rainer Strohmenger
General Partner 

WuXi Venture Fund United States

WuXi Venture Fund is the corporate venture arm of WuXi AppTec, a multinational CRO based in Shanghai China with multiple offices across China and the United States. The fund makes equity investments into technology and life science companies to enhance or leverage WuXi AppTec's platform capabilities. The investment size will be varied based on a case-by-case basis. The firm invests in life science companies across the globe with an emphasis in China and the US.

Alexis Ji
Principal 
Sofie Qiao
Managing Director